都柏林 - Jazz制药公司 (NASDAQ:JAZZ)周四发布的新闻稿显示，该公司已任命Thomas Riga为首席业务官，自2026年1月1日起生效。目前市值97亿美元的Jazz制药在过去六个月内股价飙升了55.2%。

Chimerix meets financial expectations during Q2, 2023 earnings call. Investment thesis for Chimerix focuses on its ONC201 study expected to read out in 2026. Company has high risk of loss despite ...

DURHAM, N.C., June 24, 2022 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients ...

Chimerix took quite a skid as it passed into the danger zone. Earnings for Q4, 2022 support an ongoing bull thesis for Chimerix. Wall Street Analysts have been strongly supportive of CMRX in the past ...

Chimerix, a biopharmaceutical company, announced that the New Drug Application (NDA) for its drug Dordaviprone, aimed at treating recurrent H3 K27M-mutant diffuse glioma, is under review with a ...

Chimerix cell biologist Phiroze Sethna draws samples to help him begin to grow and study new cells in his anti-viral research in 2011. Chimerix’s value has plummeted from $2.5 billion last summer to ...

Investors are furious about management's plan to sell its most valuable asset in order to chase a lackluster oncology program. Under the terms of the agreement, Chimerix will receive $225 million when ...

A side effect of the improving status of the West Africa Ebola outbreak has led Chimerix to discontinue its participation in clinical efficacy trials of their lead antiviral drug, brincidofovir ...